C.M. Bidwell & Associates’s Arcus Biosciences RCUS Stock Holding History

C.M. Bidwell & Associates’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-130	Closed	-$2.64K	–	582
2023 Q2	$2.64K	Hold	130	–	–	﹤0.01%	441
2023 Q1	$2.37K	Buy	+130	New	+$2.48K	﹤0.01%	444
2022 Q2	–	Sell	-3,015	Closed	-$95K	–	540
2022 Q1	$95K	Hold	3,015	–	–	0.06%	243
2021 Q4	$122K	Buy	+3,015	New	+$117K	0.08%	224
2021 Q2	–	Sell	-2,520	Closed	-$71K	–	612
2021 Q1	$71K	Buy	+2,520	New	+$87.7K	0.05%	269

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

C.M. Bidwell & Associates's RCUS Position: Q3 2023 in Review

C.M. Bidwell & Associates sold out of Arcus Biosciences (RCUS) in Q3 2023, closing a stake of 130 shares — an estimated $2.64K sold.

C.M. Bidwell & Associates first reported a position in RCUS in Q1 2021 and held it in 5 quarters. The position peaked at $122K in Q4 2021. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2023.

C.M. Bidwell & Associates reported no remaining Arcus Biosciences position as of Q3 2023 after selling out during the quarter.
C.M. Bidwell & Associates sold 130 Arcus Biosciences shares in Q3 2023, an estimated $2.64K.
C.M. Bidwell & Associates first reported a position in Arcus Biosciences in Q1 2021 and held it in 5 quarters.
C.M. Bidwell & Associates's Arcus Biosciences position peaked at $122K in Q4 2021.
187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2023, filed 13 Nov 2023.